title: Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.
abstract: In the EU, once-daily memantine 20 mg (Axura(®), Ebixa(®)) is an option for the management of patients with moderate to severe Alzheimer's disease (AD). In pooled clinical trials and studies in the clinical practice setting, memantine 20 mg/day improved cognition, functional ability and behavioural symptoms in this patient population. The beneficial effects of memantine are associated with delays in the need for full-time care, which were predicted to result in cost savings relative to standard care in recent cost-utility analyses in patients with moderate to severe AD conducted in EU countries. Memantine is well tolerated, with an adverse event profile that is similar to that with placebo.
authors.affiliation: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, New Zealand. dra@adis.com
authors.forename: Katherine A
authors.initials: KA
authors.lastname: Lyseng-Williamson
authors.forename: Kate
authors.initials: K
authors.lastname: McKeage
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005062:European Union; D006801:Humans; D008559:Memantine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D008559:Memantine